Marketing weight-loss injectables: a workflow that survives review

Start with what cannot be said

GLP-1 medicines and other prescription weight-loss injectables sit under the same section 42DL prohibition as cosmetic injectables. Brand names, active ingredients and product photography are off the table for public-facing content. So are indirect cues—recognisable pens, dose language, celebrity references and hashtags that stand in for the substance.

Language that promises outcomes is the next tier of risk. Specific weight-loss figures, timeframes and superiority claims require substantiation that most clinics cannot produce for their own patient cohort. The ACCC treats the overall impression of a piece as the test, not the technical wording of one sentence.

Structure the funnel so promotion and eligibility do not blur

A defensible funnel separates three surfaces: brand and service pages that promote the consultation; educational content that explains the condition, the assessment and the treatment category in neutral terms; and a gated post-consultation experience where treatment-specific information can be shared with a patient of the prescriber. Mixing these on a single landing page is where most breaches originate.

Eligibility quizzes and BMI calculators are useful when they inform, and risky when they qualify a prospect toward a specific medicine. Frame them around suitability for a consultation, not suitability for a product. Keep the copy in the assessor's voice, not the marketer's.

A channel checklist the team can actually run

Each channel has its own failure mode. Meta and TikTok reward imagery and testimonial-style content that the code restricts. Google Ads policies overlap with but do not replace TGA rules. Email is a private channel to patients but public to the regulator when forwarded. Referral partners speak on the clinic's behalf whether the clinic wants them to or not.

A one-page checklist per channel—what may be shown, what must be avoided, who approves and what evidence is filed—turns judgement into a repeatable process. It is the difference between a marketing lead who ships weekly and one who waits for legal.

• Paid social: no product cues, no outcome numbers, matched imagery only
• Search: keyword and ad copy reviewed together, not separately
• Email: patient-only lists, documented consent, unsubscribe honoured
• Referrers and influencers: written brief, approved claims, disclosure

The draft, evidence, review, publish loop

The workflow that survives is boring: draft against approved claims, attach evidence to each substantive statement, route to a named clinical or compliance reviewer, record the decision, publish, then monitor. Version everything. When a regulator or platform asks, the answer is a file, not a memory.

This article is general information, not legal or medical advice. The correct approach depends on the medicine, the audience and the channel; obtain specialist advice where the risk is material.